Maze Therapeutics — Third Quarter 2026 Earnings Summary

Maze Therapeutics completed enrollment in the Phase 2 HORIZON trial for its APOL1 inhibitor MZE829, involving over 50 patients across three cohorts, with final data expected in early 2027. The company continues enrollment in the Phase 2 CIPheR trial for MZE782 in phenylketonuria and plans to initiate a Phase 2 trial for chronic kidney disease in the first half of 2027. For the third quarter ended September 30, 2026, Maze reported $477 million in cash and marketable securities, $40.2 million in research and development expenses, and a net loss of $48.0 million. The company recognized $20 million in license revenue during the first nine months of 2026 following a milestone achievement with Shionogi & Co., Ltd.